{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:12:39Z","timestamp":1790007159468,"version":"4.0.1"},"reference-count":122,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T00:00:00Z","timestamp":1634774400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.ejca.2021.10.016","type":"journal-article","created":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T13:00:27Z","timestamp":1637845227000},"page":"112-133","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer"],"prefix":"10.1016","volume":"160","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8738-5913","authenticated-orcid":false,"given":"Andrew DJ.","family":"Pearson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8672-5285","authenticated-orcid":false,"given":"Claudia","family":"Rossig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crystal","family":"Mackall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirali N.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Baruchel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Reaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosanna","family":"Ricafort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7703-9902","authenticated-orcid":false,"given":"Delphine","family":"Heenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham","family":"Bassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Berntgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Bird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0863-5655","authenticated-orcid":false,"given":"Eric","family":"Bleickardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3357-6941","authenticated-orcid":false,"given":"Najat","family":"Bouchkouj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5220-9186","authenticated-orcid":false,"given":"Carrie","family":"Brownstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5591-9730","authenticated-orcid":false,"given":"Sarah Beaussant","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7749-8423","authenticated-orcid":false,"given":"Teresa","family":"de Rojas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5981-1332","authenticated-orcid":false,"given":"Lori","family":"Ehrlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9998-5326","authenticated-orcid":false,"given":"Elizabeth","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3991-7468","authenticated-orcid":false,"given":"Stephen","family":"Gottschalk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Hanssens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3602-1375","authenticated-orcid":false,"given":"Douglas S.","family":"Hawkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan D.","family":"Horak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle H.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8903-1513","authenticated-orcid":false,"given":"Courtney","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Karres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franca","family":"Ligas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4717-7690","authenticated-orcid":false,"given":"Donna","family":"Ludwinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7178-8163","authenticated-orcid":false,"given":"Maksim","family":"Mamonkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6537-2118","authenticated-orcid":false,"given":"Lynley","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behzad K.","family":"Masouleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousif","family":"Matloub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Maude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"McDonough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"Minard-Colin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen","family":"Norga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2935-0058","authenticated-orcid":false,"given":"Karsten","family":"Nysom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Pappo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6185-1875","authenticated-orcid":false,"given":"Laura","family":"Pearce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Pieters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Pule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Quint\u00e1s-Cardama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9378-9909","authenticated-orcid":false,"given":"Nick","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Sch\u00fc\u00dfler-Lenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6539-2741","authenticated-orcid":false,"given":"Nicole","family":"Scobie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina A.","family":"Sersch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm A.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaroslav","family":"Sterba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah K.","family":"Tasian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1080-1402","authenticated-orcid":false,"given":"Brenda","family":"Weigel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L.","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian Michel","family":"Zwaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Lesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Vassal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2021.10.016_bib1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ejca.2019.01.013","article-title":"ACCELERATE and European Medicine Agency Paediatric Strategy Forum for medicinal product development for mature B-cell malignancies in children","volume":"110","author":"Pearson","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2021.10.016_bib2","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejca.2019.12.029","article-title":"ACCELERATE and European medicines agency paediatric strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients","volume":"127","author":"Pearson","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2021.10.016_bib3","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ejca.2020.04.038","article-title":"Paediatric strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents","volume":"136","author":"Pearson","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2021.10.016_bib4","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ejca.2020.08.014","article-title":"Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration","volume":"139","author":"Pearson","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2021.10.016_bib5","unstructured":"http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Report\/2017\/06\/WC500228940.pdf (Accessed 26 September 2021)."},{"key":"10.1016\/j.ejca.2021.10.016_bib6","doi-asserted-by":"crossref","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","volume":"86","author":"Gross","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ejca.2021.10.016_bib7","doi-asserted-by":"crossref","first-page":"6448","DOI":"10.1158\/1078-0432.CCR-11-0485","article-title":"SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies","volume":"17","author":"Blanc","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2021.10.016_bib8","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.15252\/emmm.201607485","article-title":"Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts","volume":"9","author":"Hartmann","year":"2017","journal-title":"Rev EMBO Mol Med"},{"key":"10.1016\/j.ejca.2021.10.016_bib9","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/s41591-019-0564-6","article-title":"Clinical lessons learned from the first leg of the CAR T cell journey","volume":"25","author":"Majzner","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2021.10.016_bib10","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41573-021-00189-2","article-title":"Navigating CAR-T cells through the solid-tumour microenvironment","volume":"20","author":"Hou","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ejca.2021.10.016_bib11","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw2127","article-title":"Driving CAR T cell translation forward","volume":"11","author":"Schultz","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ejca.2021.10.016_bib12","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1001\/jama.2021.0669","article-title":"Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemia: a randomized clinical trial","volume":"325","author":"Brown","year":"2021","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.ejca.2021.10.016_bib13","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/jama.2021.0987","article-title":"Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse B-cell acute lymphoblastic leukemia: a randomized clinical trial","volume":"325","author":"Locatelli","year":"2021","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.ejca.2021.10.016_bib14","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1200\/JCO.20.00493","article-title":"Reduced morbidity and mortality in survivors of childhood acute lymphoblastic leukemia: a report from the childhood cancer survivor study","volume":"38","author":"Dixon","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.10.016_bib15","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"10.1016\/j.ejca.2021.10.016_bib16","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1182\/blood-2018-99-112599","article-title":"Updated analysis of the efficacy and safety of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory (r\/r) acute lymphoblastic leukemia","volume":"132","author":"Grupp","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2021.10.016_bib17","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.10.016_bib18","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2021.10.016_bib19","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2021.10.016_bib20","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/s41591-019-0549-5","article-title":"Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR","volume":"25","author":"Ghorashian","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2021.10.016_bib21","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2018-11-883710","article-title":"Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy","volume":"133","author":"Hay","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2021.10.016_bib22","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma","volume":"4","author":"Pasquini","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.ejca.2021.10.016_bib23","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2021.10.016_bib24","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI125423","article-title":"CD19 CAR T cell product and disease attributes predict leukemia remission durability","volume":"129","author":"Finney","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ejca.2021.10.016_bib25","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1200\/JCO.20.03458","article-title":"Humanized CD19-targeted chimeric antigen receptor (CAR) T cells in CAR-naive and CAR-exposed children and young adults with relapsed or refractory acute lymphoblastic leukemia","volume":"39","author":"Myers","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.10.016_bib26","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1182\/bloodadvances.2019000692","article-title":"CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy","volume":"3","author":"Pillai","year":"2019","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"10.1016\/j.ejca.2021.10.016_bib27","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2020-139260","article-title":"Pre-CAR blinatumomab is associated with increased post-CD19 CAR relapse and decreased event free survival","volume":"136","author":"Taraseviciute","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2021.10.016_bib28","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-021-01281-7","article-title":"Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia","author":"Dourthe","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2021.10.016_bib29","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1200\/JCO.20.02477","article-title":"Risk-adapted preemptive tocilizumab to prevent severe cytokine release syndrome after CTL019 for pediatric B-cell acute lymphoblastic leukemia: a prospective clinical trial","volume":"39","author":"Kadauke","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.10.016_bib30","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.omto.2018.10.006","article-title":"Preclinical development of bivalent chimeric antigen receptors targeting both CD19 and CD22","volume":"11","author":"Qin","year":"2018","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.ejca.2021.10.016_bib31","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1038\/s41591-020-1081-3","article-title":"Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial","volume":"26","author":"Shah","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2021.10.016_bib32","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3389\/fonc.2014.00055","article-title":"Molecular therapeutic approaches for pediatric acute myeloid leukemia","volume":"4","author":"Tasian","year":"2014","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2021.10.016_bib33","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1182\/blood-2014-11-612903","article-title":"Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoproteins","volume":"126","author":"Qin","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2021.10.016_bib34","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2021.10.016_bib35","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1200\/JCO.19.03279","article-title":"CD4\/CD8 T-Cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase\u00a0I anti-CD22 CAR T-cell trial","volume":"38","author":"Shah","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.10.016_bib36","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1038\/s41375-019-0488-7","article-title":"CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia","volume":"33","author":"Pan","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2021.10.016_bib37","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood-2012-06-438002","article-title":"Anti -CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia","volume":"121","author":"Haso","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2021.10.016_bib38","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41375-020-0792-2","article-title":"CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression","volume":"35","author":"Fousek","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2021.10.016_bib39","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1182\/blood-2015-03-633685","article-title":"Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232","volume":"126","author":"Borowitz","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2021.10.016_bib40","unstructured":"Study of efficacy and safety of tisagenlecleucel in HR B-all EOC MRD positive patients (CASSIOPEIA). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03876769 (Accessed 26 September 2021)."},{"key":"10.1016\/j.ejca.2021.10.016_bib41","unstructured":"Study evaluating brexucabtagene autoleucel (KTE-X19) in pediatric and adolescent participants with relapsed\/refractory B-precursor acute lymphoblastic leukemia or relapsed\/refractory B-cell non-hodgkin lymphoma (ZUMA-4). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02625480 (Accessed 26 September 2021)."},{"key":"10.1016\/j.ejca.2021.10.016_bib42","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1038\/s41375-018-0071-7","article-title":"Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012","volume":"32","author":"Rasche","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2021.10.016_bib43","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3390\/jcm4010127","article-title":"Pediatric AML: from biology to clinical management","volume":"4","author":"de Rooij","year":"2015","journal-title":"J Clin Med"},{"key":"10.1016\/j.ejca.2021.10.016_bib44","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ccell.2017.09.004","article-title":"Integrating proteomics and transcriptomics for systematic combinatorial chimeric antigen receptor therapy of AML","volume":"32","author":"Perna","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2021.10.016_bib45","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3390\/biomedicines6010022","article-title":"Targeting leukemia stem cells in the Bone marrow niche","volume":"6","author":"Tasian","year":"2018","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejca.2021.10.016_bib46","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/2050-7771-2-4","article-title":"CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies","volume":"2","author":"Testa","year":"2014","journal-title":"Biomark Res"},{"key":"10.1016\/j.ejca.2021.10.016_bib47","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1182\/blood-2012-12-474056","article-title":"T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia","volume":"122","author":"Mardiros","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2021.10.016_bib48","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1182\/blood-2013-09-529537","article-title":"Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells","volume":"123","author":"Gill","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2021.10.016_bib49","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1038\/mt.2016.116","article-title":"CD123-Engager T cells as a novel immunotherapeutic for acute myeloid leukemia","volume":"24","author":"Bonifant","year":"2016","journal-title":"Mol Ther"},{"key":"10.1016\/j.ejca.2021.10.016_bib50","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/cyto.b.21745","article-title":"CD123 expression levels in 846 acute leukemia patients based on standardized immunophenotyping","volume":"96","author":"Bras","year":"2019","journal-title":"Cytometry B Clin Cytom"},{"key":"10.1016\/j.ejca.2021.10.016_bib51","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1182\/blood-2016-08-736041","article-title":"Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia","volume":"129","author":"Tasian","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2021.10.016_bib52","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.omtm.2020.06.024","article-title":"The art and science of selecting a CD123-specific chimeric antigen receptor for clinical testing","volume":"18","author":"Riberdy","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.ejca.2021.10.016_bib53","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000845","article-title":"41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in\u00a0vivo","volume":"8","author":"Baroni","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2021.10.016_bib54","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003149","article-title":"Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design","volume":"9","author":"Qin","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2021.10.016_bib55","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1200\/JCO.2014.55.3628","article-title":"Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children's Oncology Group trial AAML0531","volume":"32","author":"Gamis","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.10.016_bib56","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1182\/blood-2011-12-398370","article-title":"Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML","volume":"119","author":"Pollard","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2021.10.016_bib57","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1200\/JCO.2015.62.6846","article-title":"CD33 expression and its association with gemtuzumab ozogamicin response: results from the randomized phase III Children's oncology group trial AAML0531","volume":"34","author":"Pollard","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.10.016_bib58","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1200\/JCO.2016.71.2513","article-title":"CD33 splicing polymorphism determines gemtuzumab ozogamicin response in de novo acute myeloid leukemia: report from randomized phase III Children's oncology group trial AAML0531","volume":"35","author":"Lamba","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.10.016_bib59","unstructured":"Study of anti-CD33 chimeric antigen receptor-expressing T cells (CD33CART) in children and young adults with relapsed\/refractory acute myeloid leukemia. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03971799 (Accessed 26 September 2021)."},{"key":"10.1016\/j.ejca.2021.10.016_bib60","unstructured":"CD123-Directed autologous T-cell therapy for acute myelogenous leukemia (CATCHAML). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04318678 (Accessed 26 September 2021)."},{"key":"10.1016\/j.ejca.2021.10.016_bib61","unstructured":"CD123 redirected T cells for AML in pediatric subjects. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04678336 (Accessed 26 September 2021)."},{"issue":"Supplement 1","key":"10.1016\/j.ejca.2021.10.016_bib62","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1182\/blood-2018-99-110845","article-title":"Immunotherapeutic targeting of mesothelin in acute myeloid leukemia in\u00a0vitro with anetumab ravtansine and a novel antibody-drug conjugate","volume":"132","author":"Kaeding","year":"2018","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.ejca.2021.10.016_bib63","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1182\/blood-2018-99-115544","article-title":"Comprehensive transcriptome profiling of cryptic CBFA2T3-GLIS2 fusion-positive AML defines novel therapeutic options \u2014 a COG and target pediatric AML study","volume":"132","author":"Smith","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2021.10.016_bib64","unstructured":"Study of CAR T-cell therapy in acute myeloid leukemia and multiple myeloma https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04097301 (Accessed 26 September 2021)."},{"key":"10.1016\/j.ejca.2021.10.016_bib65","unstructured":"Chimeric antigen receptor T-cells for the treatment of AML expressing CLL-1 antigen https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04219163 (Accessed 26 September 2021)."},{"key":"10.1016\/j.ejca.2021.10.016_bib66","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3389\/fonc.2019.00126","article-title":"Chimeric antigen receptors for T-cell malignancies","volume":"9","author":"Scherer","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2021.10.016_bib67","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1182\/blood-2015-02-629527","article-title":"A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies","volume":"126","author":"Mamonkin","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2021.10.016_bib68","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood-2017-01-761320","article-title":"CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies","volume":"130","author":"Gomes-Silva","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2021.10.016_bib69","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1182\/bloodadvances.2017009928","article-title":"Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies","volume":"1","author":"Png","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.ejca.2021.10.016_bib70","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1038\/s41375-018-0065-5","article-title":"An \"off-the-shelf\u201d fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies","volume":"32","author":"Cooper","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2021.10.016_bib71","unstructured":"CD7 CAR-T cells for patients with R\/R CD7+ NK\/T cell Lymphoma,T-lymphoblastic lymphoma and acute lymphocytic leukemia. https:\/\/clinicaltrials.gov\/ct2\/showNCT04004637."},{"key":"10.1016\/j.ejca.2021.10.016_bib72","unstructured":"Anti-CD7 U-CAR-T cell therapy for T\/NK cell hematologic malignancies. https:\/\/clinicaltrials.gov\/ct2\/showNCT04264078 (Accessed 26 September 2021)."},{"key":"10.1016\/j.ejca.2021.10.016_bib73","unstructured":"CD7 CAR-T cells for patients with R\/R CD7+ NK\/T cell Lymphoma,T-lymphoblastic lymphoma and acute lymphocytic leukemia. https:\/\/clinicaltrials.gov\/ct2\/showNCT04004637 (Accessed 26 September 2021)."},{"key":"10.1016\/j.ejca.2021.10.016_bib74","first-page":"JCO2100389","article-title":"Donor-derived CD7 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia: first-in-human, phase I trial","author":"Pan","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.10.016_bib75","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1158\/1078-0432.CCR-20-1271","article-title":"Eradication of T-ALL cells by CD7-targeted universal CAR-T cells and initial test of ruxolitinib-based CRS management","volume":"27","author":"Li","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2021.10.016_bib76","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/ijc.1457","article-title":"Targeting of G(D2)-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes","volume":"94","author":"Rossig","year":"2001","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2021.10.016_bib77","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/nm.1882","article-title":"Virus-specific T cells engineered to coexpress\u00a0tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma","volume":"14","author":"Pule","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2021.10.016_bib78","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd6169","article-title":"Antitumor activity without on-target off-tumor toxicity of GD2-chimeric antigen receptor T cells in patients with neuroblastoma","volume":"12","author":"Straathof","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ejca.2021.10.016_bib79","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2021.10.016_bib80","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1433518","article-title":"Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma","volume":"7","author":"Quintarelli","year":"2018","journal-title":"OncoImmunology"},{"key":"10.1016\/j.ejca.2021.10.016_bib81","unstructured":"Anti-GD2 CAR T cells in pediatric patients affected by high risk and\/or relapsed\/refractory neuroblastoma or other GD2-positive solid tumors. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03373097 (Accessed 26 September 2021)."},{"key":"10.1016\/j.ejca.2021.10.016_bib82","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41591-018-0006-x","article-title":"Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M + diffuse midline gliomas","volume":"24","author":"Mount","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2021.10.016_bib83","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/s41591-020-0827-2","article-title":"Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymomas","volume":"26","author":"Donovan","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2021.10.016_bib84","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/s41591-020-0821-8","article-title":"Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid\/rhabdoid tumors","volume":"26","author":"Theruvath","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2021.10.016_bib85","unstructured":"GD2 CAR T cells in diffuse intrinsic pontine gliomas(DIPG) & spinal diffuse midline glioma(DMG) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04196413 (Accessed 26 September 2021)."},{"key":"10.1016\/j.ejca.2021.10.016_bib86","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1182\/blood-2013-11-541235","article-title":"Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy","volume":"124","author":"Heczey","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2021.10.016_bib87","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1172\/JCI37869","article-title":"Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages","volume":"119","author":"Song","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ejca.2021.10.016_bib88","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1172\/JCI59535","article-title":"IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activity","volume":"122","author":"Liu","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ejca.2021.10.016_bib89","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1038\/s41591-020-1074-2","article-title":"Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis","volume":"26","author":"Heczey","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2021.10.016_bib90","unstructured":"C7R-GD2.CART cells for patients with relapsed or refractory neuroblastoma and other GD2 positive cancers (GAIL-N). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03635632."},{"key":"10.1016\/j.ejca.2021.10.016_bib91","unstructured":"Glypican 3-specific chimeric antigen receptor expressed in T cells for patients with pediatric solid tumors (GAP). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02932956 (Accessed 26 September 2021)."},{"key":"10.1016\/j.ejca.2021.10.016_bib92","unstructured":"Interleukin-15 armored glypican 3-specific chimeric antigen receptor expressed in T cells for pediatric solid tumors. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04377932 (Accessed 26 September 2021)."},{"key":"10.1016\/j.ejca.2021.10.016_bib93","unstructured":"Interleukin-15 and -21 armored glypican-3-specific chimeric antigen receptor expressed in T cells for pediatric solid tumors. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04715191 (Accessed 26 September 2021)."},{"key":"10.1016\/j.ejca.2021.10.016_bib94","first-page":"E6623","article-title":"Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma","volume":"114","author":"Li","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ejca.2021.10.016_bib95","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1001\/jamaoncol.2017.0184","article-title":"HER2-Specific chimeric antigen receptor-modified virus-specific T cells for progressive glioblastoma: a phase 1 dose-escalation trial","volume":"3","author":"Ahmed","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2021.10.016_bib96","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1038\/s41467-020-17175-8","article-title":"Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma","volume":"11","author":"Hegde","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2021.10.016_bib97","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1158\/1078-0432.CCR-16-0354","article-title":"Preclinical assessment of CD171-directed CAR T-cell adoptive therapy for childhood neuroblastoma: CE7 epitope target safety and product manufacturing feasibility","volume":"23","author":"K\u00fcnkele","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2021.10.016_bib98","doi-asserted-by":"crossref","first-page":"7080","DOI":"10.18632\/oncotarget.27389","article-title":"EGFR806-CAR T cells selectively target a tumor-restricted EGFR epitope in glioblastoma","volume":"10","author":"Ravanpay","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejca.2021.10.016_bib99","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1158\/1078-0432.CCR-18-0432","article-title":"CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors","volume":"25","author":"Majzner","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2021.10.016_bib100","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1158\/2159-8290.CD-17-1417","article-title":"Antitumor activity associated with prolonged persistence of adoptively transferred NY-ESO-1 c259 T cells in synovial sarcoma","volume":"8","author":"D'Angelo","year":"2018","journal-title":"Cancer Discov"},{"issue":"15 suppl","key":"10.1016\/j.ejca.2021.10.016_bib101","article-title":"Phase I dose escalation and expansion trial to assess the safety and efficacy of ADP-A2M4 SPEAR T cells in advanced solid tumors","volume":"38","author":"Hong","year":"2020","journal-title":"J Clin Oncol"},{"issue":"13 Supplement","key":"10.1016\/j.ejca.2021.10.016_bib102","doi-asserted-by":"crossref","first-page":"CT105","DOI":"10.1158\/1538-7445.AM2021-CT105","article-title":"Preliminary safety and efficacy of gavocabtagene autoleucel (gavo-cel, TC-210), a T cell receptor fusion construct (TRuC), in patients with treatment refractory mesothelin overexpressing solid tumors","volume":"81","author":"Hong","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2021.10.016_bib103","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa1915315","article-title":"European intergroup for childhood non-hodgkin lymphoma; children's oncology group rituximab for high-risk, mature B-cell non-hodgkin's lymphoma in children","volume":"382","author":"Minard-Colin","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.10.016_bib104","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2021.10.016_bib105","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.10.016_bib106","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2021.10.016_bib107","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2020002394","article-title":"Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Locke","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.ejca.2021.10.016_bib108","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1182\/blood.2019002008","article-title":"Early response observed in pediatric patients with relapsed\/refractory Burkitt lymphoma treated with chimeric antigen receptor T cells","volume":"135","author":"Zhang","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2021.10.016_bib109","unstructured":"Phase II open label trial to determine safety & efficacy of tisagenlecleucel in pediatric non-hodgkin lymphoma patients (BIANCA). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03610724 (Accessed 26 September 2021)."},{"key":"10.1016\/j.ejca.2021.10.016_bib110","unstructured":"A study to evaluate the safety and efficacy of JCAR017 in pediatric subjects with relapsed\/refractory (r\/r) B-cell acute lymphoblastic leukemia (B-all) and B-cell non-hodgkin lymphoma (B-NHL). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03743246 (Accessed 26 September 2021)."},{"key":"10.1016\/j.ejca.2021.10.016_bib111","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1200\/JCO.20.01342","article-title":"Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma","volume":"38","author":"Ramos","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.10.016_bib112","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/S0140-6736(20)32334-5","article-title":"Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies","volume":"396","author":"Benjamin","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2021.10.016_bib113","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf2341","article-title":"Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia","volume":"8","author":"Romee","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ejca.2021.10.016_bib114","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1158\/2159-8290.CD-20-0312","article-title":"Multidimensional analyses of donor memory-like NK cells reveal new associations with response after adoptive immunotherapy for leukemia","volume":"10","author":"Berrien-Elliott","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2021.10.016_bib115","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.10.016_bib116","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1158\/2326-6066.CIR-18-0572","article-title":"NK cells expressing a chimeric activating receptor eliminate MDSCs and rescue impaired CAR-T cell activity against solid tumors","volume":"7","author":"Parihar","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ejca.2021.10.016_bib117","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41571-020-00456-y","article-title":"Beyond the storm \u2014 subacute toxicities and late effects in children receiving CAR T cells","volume":"18","author":"Shalabi","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2021.10.016_bib118","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1470-2045(19)30097-X","article-title":"Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study","volume":"20","author":"Tamura","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2021.10.016_bib119","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2004413","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer","volume":"382","author":"Shitara","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.10.016_bib120","doi-asserted-by":"crossref","first-page":"4227","DOI":"10.1200\/JCO.20.02152","article-title":"Accelerating the global development of pediatric cancer drugs: a call to coordinate the submissions of pediatric investigation plans and pediatric study plans to the European medicines agency and US Food and drug administration","volume":"38","author":"Reaman","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.10.016_bib121","unstructured":"Common Commentary - EMA\/FDA Common issues requested for discussion by the respective agency (EMA\/PDCO and FDA) concerning paediatric oncology development plans (Paediatric Investigation Plans [PIPs] and initial Pediatric Study Plans [iPSPs]). https:\/\/www.ema.europa.eu\/en\/human-regulatory\/research-development\/paediatric-medicines\/paediatric-investigation-plans#joint-ema-\/-fda-guidance-on-cancer-medicines-for-use-in-children-section (Accessed 26 September 2021)."},{"key":"10.1016\/j.ejca.2021.10.016_bib122","unstructured":"Common Commentary - EMA\/FDA Common issues requested for discussion by the respective agency (EMA\/PDCO and FDA) concerning paediatric oncology development plans (Paediatric Investigation Plans [PIPs] and initial Pediatric Study Plans [iPSPs]). https:\/\/www.fda.gov\/media\/147197 (Accessed 26 September 2021)."}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921011709?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921011709?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:34:08Z","timestamp":1760733248000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804921011709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":122,"alternative-id":["S0959804921011709"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2021.10.016","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.10.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}